Our study confirmed the diagnostic utility of TRBC1 across various T‐cell lymphomas, including anaplastic large‐cell lymphoma, extranodal NK/T‐cell lymphoma, peripheral T‐cell lymphoma, T‐cell prolymphocytic leukemia, follicular helper T‐cell lymphoma, and T‐LGL, while notably showing a predominance (65%) of TRBC1− (potentially TRBC2+) cases, which may have significant implications for predicting patient populations suitable for emerging TRBC1 and TRBC2 targeted therapies [20, 21]. Here, TRBC2 is linked to T-cell large granular lymphocyte leukemia.